Recommendations repealed

8.5.2025 Summary of COHERE Finland's recommendation on Nirsevimab in the prevention of lower respiratory tract infection caused by respiratory syncytial virus (RSV). Approved at the meeting of COHERE on 7 May 2024. This recommendation is no longer in force but has been replaced by a recommendation approved by COHERE on 8 May 2025. Link to the replacing recommendation.

4.2.2022  Recommendation: ''Criteria for continued treatment with nusinersen.'' Approved at the meeting of COHERE on 4 September 2019.

4.2.2022 Nusinersen in treating Spinal Muscular Atropy (SMA) - Approved at the meeting of COHERE on 15 March 2018.